Even if you have previously told us how you would like to hear from us and/or you have supported us for many years, new data protection legislation requires you to provide your explicit consent in order for us to continue to contact you in the ways that are important to you.
Please use this form to tell us your preferences. You can also change your mind at any time – you will find further details about how to do this below. In the future, we will only contact you about the areas of our work you choose via the communication methods you prefer. Please complete all fields.
We are pleased to share the latest update from Orphazyme entitled 'Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)'.Read more
CTD Holdings: Annual conference offers opportunities for academic researchers and industry representatives to exchange information on novel therapeutic interventions...Read more